U.S. Facial Injectable Market Size to Hit USD 12.40 Billion By 2033

U.S. Facial Injectable Market Size to Hit USD 12.40 Billion By 2033

According to latest report the U.S. facial injectable market size was USD 4.25 billion in 2023, calculated at USD 4.73 billion in 2024 and is expected to reach around USD 12.40 billion by 2033, expanding at a CAGR of 11.3% from 2024 to 2033.

Increasing focus on facial appearance and increasing acceptance of facial injectable are some of the major factors driving market growth. According to Plastic Surgery Statistics 2023 report by the American Society of Plastic Surgeons, neuromodulator injection procedures performed in the U.S. have increased by 73% from 5,043,057 in 2019 to 8,736,591 in 2023. This increasing acceptance of facial injectable in the country is expected to drive market growth over forecast period.

Facial injectable are primarily used as cosmetic products for enhancing facial structure and appearance. Moreover, facial injectable offer an effective solution to wrinkles and facial lines, which has increased their popularity among country’s geriatric population. According to the U.S. Census Bureau 2020 census, elderly population in the U.S. grew at growth rate of 38.6% from 40.3 million in 2010 to 55.8 million in 2020, which is the fastest growth rate since 1880-1890. This increasing geriatric population of the country is boosting demand for facial injectable, thereby contributing to the growth of the market.

The U.S. is one of the major contributors to cosmetic surgeries performed globally, owing to the country's high awareness of cosmetic surgeries and procedures. This awareness increases the number of cosmetic non-surgical procedures performed in the country. Facial injectable offer a non-surgical alternative to other aesthetic surgical procedures. According to Aesthetic Society’s 2023 report, total non-surgical aesthetic procedures in the U.S. witnessed a rise of 23% in 2023. This increasing popularity and acceptance of non-surgical aesthetic procedures is expected to drive market growth over the forecast period.

Moreover, market players are focused on developing advanced solutions to meet various customer demands. This increasing focus on developing new solutions increases demand for facial injectable in different customer bases. For instance, in March 2024, Allergan Aesthetics announced FDA approval of JUVéDERM VOLUMA XC to improve temple hollowing in adults above 21 years. This Hyaluronic Acid (HA) filler addresses the needs of patients seeking a solution for temple hollowing. Such increasing focus of market players on developing demand-specific solutions is anticipated to drive market growth.

Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8608

U.S. Facial Injectable Market Key Takeaways:

  • Botulinum toxin type A dominated the market and accounted for a share of 55.45% in 2023.
  • HA is expected to grow at the fastest over the forecast period.
  • Facial line correction accounted for the largest revenue share in 2023.
  • MedSpa accounted for the largest revenue share 49.0% in 2023.
  • Dermatology clinics are anticipated to grow at a significant CAGR over the forecast period.

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8608

U.S. Facial Injectable Market By Product Insights

Botulinum toxin type A dominated the market and accounted for a share of 55.45% in 2023. Botulinum toxin works by regulating the nerve signal to reach muscles, which restricts the muscles from contracting. It has a wide range of applications, such as the treatment of wrinkles, face lines, crow’s feet, lateral canthus, forehead, and glabellar lines. These applications of botulinum toxin A have significantly contributed to its demand for cosmetic procedures.

HA is expected to grow at the fastest over the forecast period. This can be attributed to the increasing demand for injectable Hyaluronic Acid (HA) owing to its several applications, such as reducing facial folds and face wrinkles and providing special structure and framework to lips and face. Moreover, several market players are developing hyaluronic fillers to address various conditions, which is expected to increase the demand for HA injectable over the forecast period. For instance, in June 2023, Galderma announced that the company had received FDA approval for Restylane Eyelight, a HA filler for the treatment of undereye hollows in adults over 21 years.

U.S. Facial Injectable Market By Application Insights

Facial line correction accounted for the largest revenue share in 2023. This can be attributed to the increasing acceptance of facial injectable in the elderly population for the treatment of facial lines or wrinkles. Facial injectable offer a fast, effective, and lasting solution to facial lines and wrinkles over other alternatives, such as topical creams and facial implants. This has increased the preference for facial injectable for face line correction in the aging population. For instance, according to the Plastic Surgery Statistics 2023 report by The American Society of Plastic Surgeons, Gen X (born between the mid-1960s and early 1980s) leads in the procedure of neuromodulator injections with a share of 57%, which is used for wrinkle relaxing.

Lip augmentation is expected to grow at a significant CAGR over the forecast period owing to the increasing societal emphasis on better physical appearance and beauty standards. Lip augmentation is a cosmetic procedure for enhancing the shape and size of lips for a better appearance. Moreover, the country has witnessed a surge in demand for lip enhancement surgery in the past few years. For instance, according to The Aesthetic Society statistics 2020-2021, the number of lip enhancement procedures in the U.S. increased by 51% from 7,099 procedures in 2020 to 10,691 in 2021. This increasing demand for lip enhancement procedures is expected to drive the segment growth over the forecast period.

U.S. Facial Injectable Market By End-use Insights

MedSpa accounted for the largest revenue share 49.0% in 2023 and is expected to grow at the fastest CAGR over the forecast period. This can be attributed to the increasing preference of patients to get treatment from specialized facilities such as med spas. According to the American Med Spa Association (AmSpa), the number of med spas in the U.S. has increased from 7,430 in 2021 to 8,841 in 2023. This increasing number of med spas in the country is further increasing the accessibility and availability of these centers, contributing to their growth.

Dermatology clinics are anticipated to grow at a significant CAGR over the forecast period. These clinics are specialized in providing treatment for skin diseases. These specialized centers offer proper consultation and care to the patients, which increases the patient's preference towards these centers. Moreover, dermatology clinics offer personalized care and treatment history-based injectable and fillers, which is expected to contribute to their growth over the forecast period.

U.S. Facial Injectable Market Concentration & Characteristics

The U.S. market growth stage is high, and pace of the market growth is accelerating. The market is characterized by a high degree of innovation owing to increasing focus of market players on developing more effective and specialized solutions to treat specific conditions. Moreover, increasing focus on developing solutions with least allergic risk and larger impact duration significantly increases the scope for innovation in the market. For instance, in May 2023, Allergan Aesthetics announced the U.S. FDA approval of SKINVIVE by JUVéDERM. This injectable helps in improving cheek and skin smoothness with a six-month lasting effect with optimal treatment.

The market is characterized by a medium level of merger and acquisition (M&A) activity by the leading players. This is due to the increasing efforts of market players to grab opportunities offered by the increasing demand for facial injectable in the country.

The regulatory framework has a significant impact on the U.S. facial injectable market. The FDA looks after safety and use of facial injectable in the country, and approves use of dermal filler for adults above 21 years. However, it recommends against use of these fillers for body contouring and enhancement of different body parts. Adoption of such a stringent regulatory framework by the FDA significantly impacts market growth.

There is a significant range of products available as facial injectable alternatives. For instance, topical creams, laser resurfacing, skin-tightening products, and facial implants. These alternatives can offer similar solutions delivered by the facial injectable.

End-user concentration is a significant factor in the market as the customers opting for facial injectable have different alternatives, such as hospitals, med spas, and dermatology clinics. Thus, the end-user significantly depends on the customer preferences, demands, care, and results provided by these facilities.

U.S. Facial Injectable Market Recent Developments

  • In February 2023, Merz Aesthetics announced the launch of Radiesse (+), an injectable jawline contour improvement in adults over 21. This launch offered patients a non-surgical and effective option to address jawline contour.
  • In December 2021, Teoxane, a REVANCE AESTHETICS partner, received the U.S. FDA approval for its RHA, Redensity’s first indication for treating perioral rhytids (lip lines) in adults over 21. This approval increases the company’s RHA collection of derma fillers.
  • In May 2020, Galderma announced the U.S. FDA approval for its Restylane Kysse, a hyaluronic acid (HA) filler for lip augmentation and upper perioral rhytids correction. Restylane Kysse offers consistent results, high satisfaction and proven clinical safety profile for both patients and providers.

Some of the prominent players in the U.S. facial injectable market include:

  • AbbVie, Inc.
  • REVANCE AESTHETICS
  • Merz North America, Inc.
  • Galderma Laboratories, L.P.
  • Suneva Medical Inc.
  • Cytophil, Inc
  • Prollenium Medical Technologies

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. facial injectable market

Product

  • Collagen & PMMA Microspheres
  • Botulinum Toxin Type A
  • HA
  • CaHA
  • PLLA
  • Others

Application

  • Facial Line Correction
  • Lip Augmentation
  • Face Lift
  • Acne Scar Treatment
  • Lipoatrophy Treatment
  • Others

End-use

  • MedSpa
  • Dermatology Clinics
  • Hospitals

Regional

  • West
  • Midwest
  • Northeast
  • Southwest
  • Southeast

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/8608

Reasons to Purchase this Report

  • Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to com

Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.novaoneadvisor.com/report/checkout/8608

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: [email protected]

Web: https://www.novaoneadvisor.com/

要查看或添加评论,请登录

Laxman Dige的更多文章

社区洞察

其他会员也浏览了